person · Reporting owner
Stolarski Anthony Michael
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SANUWAVE Health, Inc.
Report date March 01, 2019 · Filed June 12, 2025
Section 16 reporting ended · disclosed 2025-06-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 351,786 |
Ending reported balance
After 2024-10-18 transaction · row 9
9 source rows · reconciled sequenceRow 1 · 2023-08-05 · Conversion · Acquired 103,114 · Balance 148,473 F1: Pursuant to the terms of the Future Advance Convertible Promissory Note issued by SANUWAVE Health, Inc. (the "Company") on August 5, 2022, all principal and accrued interest due as of the maturity date, August 5, 2023, was automatically converted into shares of common stock at a conversion price of $15.00 per share. Row 2 · 2023-11-14 · Conversion · Acquired 6,900 · Balance 155,373 F2: Pursuant to the terms of the Future Advance Convertible Promissory Note issued by the Company on November 14, 2022, all principal and accrued interest due as of the maturity date, November 14, 2023, was automatically converted into shares of common stock at a conversion price of $15.00 per share. Row 3 · 2024-10-18 · Grant · Acquired 80,698 · Balance 236,071 F3: On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's outstanding Future Advance Convertible Promissory Note and Common Stock Purchase Warrants were exchanged for an aggregate of 196,413 shares of common stock pursuant to a letter agreement between the reporting person and the Company. Row 4 · 2024-10-18 · Grant · Acquired 76,215 · Balance 312,286 F3: On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's outstanding Future Advance Convertible Promissory Note and Common Stock Purchase Warrants were exchanged for an aggregate of 196,413 shares of common stock pursuant to a letter agreement between the reporting person and the Company. Row 5 · 2024-10-18 · Grant · Acquired 5,400 · Balance 317,686 F3: On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's outstanding Future Advance Convertible Promissory Note and Common Stock Purchase Warrants were exchanged for an aggregate of 196,413 shares of common stock pursuant to a letter agreement between the reporting person and the Company. Row 6 · 2024-10-18 · Grant · Acquired 5,100 · Balance 322,786 F3: On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's outstanding Future Advance Convertible Promissory Note and Common Stock Purchase Warrants were exchanged for an aggregate of 196,413 shares of common stock pursuant to a letter agreement between the reporting person and the Company. Row 7 · 2024-10-18 · Grant · Acquired 11,500 · Balance 334,286 F3: On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's outstanding Future Advance Convertible Promissory Note and Common Stock Purchase Warrants were exchanged for an aggregate of 196,413 shares of common stock pursuant to a letter agreement between the reporting person and the Company. Row 8 · 2024-10-18 · Grant · Acquired 9,000 · Balance 343,286 F3: On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's outstanding Future Advance Convertible Promissory Note and Common Stock Purchase Warrants were exchanged for an aggregate of 196,413 shares of common stock pursuant to a letter agreement between the reporting person and the Company. Row 9 · 2024-10-18 · Grant · Acquired 8,500 · Balance 351,786 F3: On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's outstanding Future Advance Convertible Promissory Note and Common Stock Purchase Warrants were exchanged for an aggregate of 196,413 shares of common stock pursuant to a letter agreement between the reporting person and the Company. |
| Class O Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.25 · Expires 2019-03-17 | Direct | 0 |
Reported balance
After 2019-03-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-03-01 · Disposition to issuer · Disposed 533 · Balance 0 F4: On March 1, 2019, the Company extended the expiration date of the Class O Warrants to June 28, 2019. |
| Class O Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.25 · Expires 2019-06-28 | Direct | 533 |
Reported balance
After 2019-03-01 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2019-03-01 · Grant · Acquired 533 · Balance 533 F4: On March 1, 2019, the Company extended the expiration date of the Class O Warrants to June 28, 2019. |
| Class O Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.25 · Expires 2019-06-28 | Direct | 0 |
Reported balance
After 2019-05-31 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2019-05-31 · Disposition to issuer · Disposed 533 · Balance 0 F5: On May 31, 2019, the Company extended the expiration date of the Class O Warrants to September 3, 2019. |
| Class O Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.25 · Expires 2019-09-03 | Direct | 533 |
Reported balance
After 2019-05-31 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2019-05-31 · Grant · Acquired 533 · Balance 533 F5: On May 31, 2019, the Company extended the expiration date of the Class O Warrants to September 3, 2019. |
| Future Advance Convertible Promissory NoteSEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2023-08-05 | Direct | Not disclosed |
Reported balance
After 2022-08-05 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2022-08-05 · Grant · Acquired Not disclosed · Balance Not disclosed F6: On August 5, 2022, in exchange for the discharge of $1,344,966 owed by the Company to the reporting person, the reporting person acquired from the Company a Future Advance Convertible Promissory Note with a principal amount of $1,344,966 and a conversion price of $15.00 per share of common stock and two warrants (one exercisable for 89,664 shares of common stock at an exercise price of $15.00 per share and the other exercisable for 89,664 shares of common stock at an exercise price of approximately $25.13 per share). |
| Future Advance Convertible Promissory NoteSEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2023-08-05 | Direct | 0 |
Reported balance
After 2023-08-05 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2023-08-05 · Conversion · Disposed Not disclosed · Balance 0 F1: Pursuant to the terms of the Future Advance Convertible Promissory Note issued by SANUWAVE Health, Inc. (the "Company") on August 5, 2022, all principal and accrued interest due as of the maturity date, August 5, 2023, was automatically converted into shares of common stock at a conversion price of $15.00 per share. |
| Future Advance Convertible Promissory NoteSEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2023-11-14 | Direct | Not disclosed |
Reported balance
After 2022-11-14 transaction · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · 2022-11-14 · Grant · Acquired Not disclosed · Balance Not disclosed F7: On November 14, 2022, in exchange for $90,000 in cash, the reporting person acquired from the Company a Future Advance Convertible Promissory Note with a principal amount of $90,000 and a conversion price of $15.00 per share of common stock and two warrants (one exercisable for 6,000 shares of common stock at an exercise price of $15.00 per share and the other exercisable for 6,000 shares of common stock at an exercise price of approximately $25.13 per share). |
| Future Advance Convertible Promissory NoteSEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2023-11-14 | Direct | 0 |
Reported balance
After 2023-11-14 transaction · row 21
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 21 · 2023-11-14 · Conversion · Disposed Not disclosed · Balance 0 F2: Pursuant to the terms of the Future Advance Convertible Promissory Note issued by the Company on November 14, 2022, all principal and accrued interest due as of the maturity date, November 14, 2023, was automatically converted into shares of common stock at a conversion price of $15.00 per share. |
| Future Advance Convertible Promissory NoteSEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2025-01-21 | Direct | Not disclosed |
Reported balance
After 2024-01-21 transaction · row 28
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 28 · 2024-01-21 · Grant · Acquired Not disclosed · Balance Not disclosed F8: On July 21, 2023, in exchange for $100,000 in cash, the reporting person acquired from the Company an Asset-Backed Secured Promissory Note with a principal amount of $149,992.50. Pursuant to a letter agreement between the Company and the reporting person, dated as of July 21, 2023, the Company agreed to issue to the reporting person on January 21, 2024 a Future Advance Convertible Promissory Note with a principal amount of $149,992.50 and two Common Stock Purchase Warrants, one with an exercise price of $15.00 per share and one with an exercise price of $25.13 per share, each of which were exercisable for 9,999 shares of common stock. |
| Future Advance Convertible Promissory NoteSEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2025-01-21 | Direct | 0 |
Reported balance
After 2024-10-18 transaction · row 29
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 29 · 2024-10-18 · Disposition to issuer · Disposed Not disclosed · Balance 0 F3: On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's outstanding Future Advance Convertible Promissory Note and Common Stock Purchase Warrants were exchanged for an aggregate of 196,413 shares of common stock pursuant to a letter agreement between the reporting person and the Company. |
| Common Stock Purchase Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2027-08-05 | Direct | 89,664 |
Reported balance
After 2022-08-05 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2022-08-05 · Grant · Acquired 89,664 · Balance 89,664 F6: On August 5, 2022, in exchange for the discharge of $1,344,966 owed by the Company to the reporting person, the reporting person acquired from the Company a Future Advance Convertible Promissory Note with a principal amount of $1,344,966 and a conversion price of $15.00 per share of common stock and two warrants (one exercisable for 89,664 shares of common stock at an exercise price of $15.00 per share and the other exercisable for 89,664 shares of common stock at an exercise price of approximately $25.13 per share). |
| Common Stock Purchase Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2027-08-05 | Direct | 0 |
Reported balance
After 2024-10-18 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2024-10-18 · Disposition to issuer · Disposed 89,664 · Balance 0 F3: On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's outstanding Future Advance Convertible Promissory Note and Common Stock Purchase Warrants were exchanged for an aggregate of 196,413 shares of common stock pursuant to a letter agreement between the reporting person and the Company. |
| Common Stock Purchase Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.13 · Expires 2027-08-05 | Direct | 89,664 |
Reported balance
After 2022-08-05 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2022-08-05 · Grant · Acquired 89,664 · Balance 89,664 F6: On August 5, 2022, in exchange for the discharge of $1,344,966 owed by the Company to the reporting person, the reporting person acquired from the Company a Future Advance Convertible Promissory Note with a principal amount of $1,344,966 and a conversion price of $15.00 per share of common stock and two warrants (one exercisable for 89,664 shares of common stock at an exercise price of $15.00 per share and the other exercisable for 89,664 shares of common stock at an exercise price of approximately $25.13 per share). |
| Common Stock Purchase Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.13 · Expires 2027-08-05 | Direct | 0 |
Reported balance
After 2024-10-18 transaction · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · 2024-10-18 · Disposition to issuer · Disposed 89,664 · Balance 0 F3: On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's outstanding Future Advance Convertible Promissory Note and Common Stock Purchase Warrants were exchanged for an aggregate of 196,413 shares of common stock pursuant to a letter agreement between the reporting person and the Company. |
| Common Stock Purchase Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2027-11-14 | Direct | 6,000 |
Reported balance
After 2022-11-14 transaction · row 22
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 22 · 2022-11-14 · Grant · Acquired 6,000 · Balance 6,000 F7: On November 14, 2022, in exchange for $90,000 in cash, the reporting person acquired from the Company a Future Advance Convertible Promissory Note with a principal amount of $90,000 and a conversion price of $15.00 per share of common stock and two warrants (one exercisable for 6,000 shares of common stock at an exercise price of $15.00 per share and the other exercisable for 6,000 shares of common stock at an exercise price of approximately $25.13 per share). |
| Common Stock Purchase Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2027-11-14 | Direct | 0 |
Reported balance
After 2024-10-18 transaction · row 23
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 23 · 2024-10-18 · Disposition to issuer · Disposed 6,000 · Balance 0 F3: On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's outstanding Future Advance Convertible Promissory Note and Common Stock Purchase Warrants were exchanged for an aggregate of 196,413 shares of common stock pursuant to a letter agreement between the reporting person and the Company. |
| Common Stock Purchase Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.13 · Expires 2027-11-14 | Direct | 6,000 |
Reported balance
After 2022-11-14 transaction · row 24
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 24 · 2022-11-14 · Grant · Acquired 6,000 · Balance 6,000 F7: On November 14, 2022, in exchange for $90,000 in cash, the reporting person acquired from the Company a Future Advance Convertible Promissory Note with a principal amount of $90,000 and a conversion price of $15.00 per share of common stock and two warrants (one exercisable for 6,000 shares of common stock at an exercise price of $15.00 per share and the other exercisable for 6,000 shares of common stock at an exercise price of approximately $25.13 per share). |
| Common Stock Purchase Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.13 · Expires 2027-11-14 | Direct | 0 |
Reported balance
After 2024-10-18 transaction · row 25
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 25 · 2024-10-18 · Disposition to issuer · Disposed 6,000 · Balance 0 F3: On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's outstanding Future Advance Convertible Promissory Note and Common Stock Purchase Warrants were exchanged for an aggregate of 196,413 shares of common stock pursuant to a letter agreement between the reporting person and the Company. |
| Common Stock Purchase Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2029-01-21 | Direct | 9,999 |
Reported balance
After 2024-01-21 transaction · row 30
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 30 · 2024-01-21 · Grant · Acquired 9,999 · Balance 9,999 F8: On July 21, 2023, in exchange for $100,000 in cash, the reporting person acquired from the Company an Asset-Backed Secured Promissory Note with a principal amount of $149,992.50. Pursuant to a letter agreement between the Company and the reporting person, dated as of July 21, 2023, the Company agreed to issue to the reporting person on January 21, 2024 a Future Advance Convertible Promissory Note with a principal amount of $149,992.50 and two Common Stock Purchase Warrants, one with an exercise price of $15.00 per share and one with an exercise price of $25.13 per share, each of which were exercisable for 9,999 shares of common stock. |
| Common Stock Purchase Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2029-01-21 | Direct | 0 |
Reported balance
After 2024-10-18 transaction · row 31
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 31 · 2024-10-18 · Disposition to issuer · Disposed 9,999 · Balance 0 F3: On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's outstanding Future Advance Convertible Promissory Note and Common Stock Purchase Warrants were exchanged for an aggregate of 196,413 shares of common stock pursuant to a letter agreement between the reporting person and the Company. |
| Common Stock Purchase Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.13 · Expires 2029-01-21 | Direct | 9,999 |
Reported balance
After 2024-01-21 transaction · row 32
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 32 · 2024-01-21 · Grant · Acquired 9,999 · Balance 9,999 F8: On July 21, 2023, in exchange for $100,000 in cash, the reporting person acquired from the Company an Asset-Backed Secured Promissory Note with a principal amount of $149,992.50. Pursuant to a letter agreement between the Company and the reporting person, dated as of July 21, 2023, the Company agreed to issue to the reporting person on January 21, 2024 a Future Advance Convertible Promissory Note with a principal amount of $149,992.50 and two Common Stock Purchase Warrants, one with an exercise price of $15.00 per share and one with an exercise price of $25.13 per share, each of which were exercisable for 9,999 shares of common stock. |
| Common Stock Purchase Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.13 · Expires 2029-01-21 | Direct | 0 |
Reported balance
After 2024-10-18 transaction · row 33
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 33 · 2024-10-18 · Disposition to issuer · Disposed 9,999 · Balance 0 F3: On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's outstanding Future Advance Convertible Promissory Note and Common Stock Purchase Warrants were exchanged for an aggregate of 196,413 shares of common stock pursuant to a letter agreement between the reporting person and the Company. |
| Asset-Backed Secured Promissory NoteSEC Table II · derivative / convertible security · Expires 2024-01-21 | Direct | Not disclosed |
Reported balance
After 2023-07-21 transaction · row 26
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 26 · 2023-07-21 · Grant · Acquired Not disclosed · Balance Not disclosed F8: On July 21, 2023, in exchange for $100,000 in cash, the reporting person acquired from the Company an Asset-Backed Secured Promissory Note with a principal amount of $149,992.50. Pursuant to a letter agreement between the Company and the reporting person, dated as of July 21, 2023, the Company agreed to issue to the reporting person on January 21, 2024 a Future Advance Convertible Promissory Note with a principal amount of $149,992.50 and two Common Stock Purchase Warrants, one with an exercise price of $15.00 per share and one with an exercise price of $25.13 per share, each of which were exercisable for 9,999 shares of common stock. |
| Asset-Backed Secured Promissory NoteSEC Table II · derivative / convertible security · Expires 2024-01-21 | Direct | Not disclosed |
Reported balance
After 2024-01-21 transaction · row 27
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 27 · 2024-01-21 · Disposition to issuer · Disposed Not disclosed · Balance Not disclosed F8: On July 21, 2023, in exchange for $100,000 in cash, the reporting person acquired from the Company an Asset-Backed Secured Promissory Note with a principal amount of $149,992.50. Pursuant to a letter agreement between the Company and the reporting person, dated as of July 21, 2023, the Company agreed to issue to the reporting person on January 21, 2024 a Future Advance Convertible Promissory Note with a principal amount of $149,992.50 and two Common Stock Purchase Warrants, one with an exercise price of $15.00 per share and one with an exercise price of $25.13 per share, each of which were exercisable for 9,999 shares of common stock. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.20 · Expires 2034-10-22 | Direct | 41,333 |
Reported balance
After 2024-10-22 transaction · row 34
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 34 · 2024-10-22 · Grant · Acquired 41,333 · Balance 41,333 F9: Options will vest over a period of three years in 12 equal installments on each quarterly anniversary of the grant date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.76 · Expires 2029-12-31 | Direct | 1,559 |
Reported balance
After 2024-12-31 transaction · row 35
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 35 · 2024-12-31 · Grant · Acquired 1,559 · Balance 1,559 F10: Options were fully vested at the grant date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.80 · Expires 2030-04-03 | Direct | 1,761 |
Reported balance
After 2025-04-03 transaction · row 36
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 36 · 2025-04-03 · Grant · Acquired 1,761 · Balance 1,761 F10: Options were fully vested at the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Future Advance Convertible Promissory Note issued by SANUWAVE Health, Inc. (the "Company") on August 5, 2022, all principal and accrued interest due as of the maturity date, August 5, 2023, was automatically converted into shares of common stock at a conversion price of $15.00 per share.
F2: Pursuant to the terms of the Future Advance Convertible Promissory Note issued by the Company on November 14, 2022, all principal and accrued interest due as of the maturity date, November 14, 2023, was automatically converted into shares of common stock at a conversion price of $15.00 per share.
F3: On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's outstanding Future Advance Convertible Promissory Note and Common Stock Purchase Warrants were exchanged for an aggregate of 196,413 shares of common stock pursuant to a letter agreement between the reporting person and the Company.
F4: On March 1, 2019, the Company extended the expiration date of the Class O Warrants to June 28, 2019.
F5: On May 31, 2019, the Company extended the expiration date of the Class O Warrants to September 3, 2019.
F6: On August 5, 2022, in exchange for the discharge of $1,344,966 owed by the Company to the reporting person, the reporting person acquired from the Company a Future Advance Convertible Promissory Note with a principal amount of $1,344,966 and a conversion price of $15.00 per share of common stock and two warrants (one exercisable for 89,664 shares of common stock at an exercise price of $15.00 per share and the other exercisable for 89,664 shares of common stock at an exercise price of approximately $25.13 per share).
F7: On November 14, 2022, in exchange for $90,000 in cash, the reporting person acquired from the Company a Future Advance Convertible Promissory Note with a principal amount of $90,000 and a conversion price of $15.00 per share of common stock and two warrants (one exercisable for 6,000 shares of common stock at an exercise price of $15.00 per share and the other exercisable for 6,000 shares of common stock at an exercise price of approximately $25.13 per share).
F8: On July 21, 2023, in exchange for $100,000 in cash, the reporting person acquired from the Company an Asset-Backed Secured Promissory Note with a principal amount of $149,992.50. Pursuant to a letter agreement between the Company and the reporting person, dated as of July 21, 2023, the Company agreed to issue to the reporting person on January 21, 2024 a Future Advance Convertible Promissory Note with a principal amount of $149,992.50 and two Common Stock Purchase Warrants, one with an exercise price of $15.00 per share and one with an exercise price of $25.13 per share, each of which were exercisable for 9,999 shares of common stock.
F9: Options will vest over a period of three years in 12 equal installments on each quarterly anniversary of the grant date.
F10: Options were fully vested at the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 03, 2025 Filed Jun 12, 2025 16:18 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | GrantStock Option (right to buy) · Derivative | 1,761 | $0.00 Strike: $29.80 | $0.00 |
DisclosureSEC source: 0001437749-25-020194 · rdgdoc.xml · derivative · entry 36 Stolarski Anthony Michael · CIK 0001683425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,761 Underlying: Common Stock · 1,761 shares Expires 2030-04-03 F10 · derivative.exercise_date: Options were fully vested at the grant date. Read SEC document |
| December 31, 2024 Filed Jun 12, 2025 16:18 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | GrantStock Option (right to buy) · Derivative | 1,559 | $0.00 Strike: $22.76 | $0.00 |
DisclosureSEC source: 0001437749-25-020194 · rdgdoc.xml · derivative · entry 35 Stolarski Anthony Michael · CIK 0001683425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,559 Underlying: Common Stock · 1,559 shares Expires 2029-12-31 F10 · derivative.exercise_date: Options were fully vested at the grant date. Read SEC document |
| October 22, 2024 Filed Jun 12, 2025 16:18 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | GrantStock Option (right to buy) · Derivative | 41,333 | $0.00 Strike: $14.20 | $0.00 |
DisclosureSEC source: 0001437749-25-020194 · rdgdoc.xml · derivative · entry 34 Stolarski Anthony Michael · CIK 0001683425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,333 Underlying: Common Stock · 41,333 shares Expires 2034-10-22 F9 · derivative.exercise_date: Options will vest over a period of three years in 12 equal installments on each quarterly anniversary of the grant date. Read SEC document |
| October 18, 2024 Filed Jun 12, 2025 16:18 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | Disposition to issuerCommon Stock Purchase Warrant (right to buy) · Derivative | 9,999 | Not disclosed Strike: $25.13 | Not disclosed |
DisclosureSEC source: 0001437749-25-020194 · rdgdoc.xml · derivative · entry 33 Stolarski Anthony Michael · CIK 0001683425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,999 shares Expires 2029-01-21 F3 · shares: On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's outstanding Future Advance Convertible Promissory Note and Common Stock Purchase Warrants were exchanged for an aggregate of 196,413 shares of common stock pursuant to a letter agreement between the reporting person and the Company. F3 · price: On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's outstanding Future Advance Convertible Promissory Note and Common Stock Purchase Warrants were exchanged for an aggregate of 196,413 shares of common stock pursuant to a letter agreement between the reporting person and the Company. Read SEC document |
| October 18, 2024 Filed Jun 12, 2025 16:18 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | Disposition to issuerCommon Stock Purchase Warrant (right to buy) · Derivative | 9,999 | Not disclosed Strike: $15.00 | Not disclosed |
DisclosureSEC source: 0001437749-25-020194 · rdgdoc.xml · derivative · entry 31 Stolarski Anthony Michael · CIK 0001683425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,999 shares Expires 2029-01-21 F3 · shares: On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's outstanding Future Advance Convertible Promissory Note and Common Stock Purchase Warrants were exchanged for an aggregate of 196,413 shares of common stock pursuant to a letter agreement between the reporting person and the Company. F3 · price: On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's outstanding Future Advance Convertible Promissory Note and Common Stock Purchase Warrants were exchanged for an aggregate of 196,413 shares of common stock pursuant to a letter agreement between the reporting person and the Company. Read SEC document |
| October 18, 2024 Filed Jun 12, 2025 16:18 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | Disposition to issuerFuture Advance Convertible Promissory Note · Derivative | Not disclosed | $0.00 Strike: $15.00 | $172,491.38 |
DisclosureSEC source: 0001437749-25-020194 · rdgdoc.xml · derivative · entry 29 Stolarski Anthony Michael · CIK 0001683425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,500 shares Expires 2025-01-21 F3 · reported_value: On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's outstanding Future Advance Convertible Promissory Note and Common Stock Purchase Warrants were exchanged for an aggregate of 196,413 shares of common stock pursuant to a letter agreement between the reporting person and the Company. Read SEC document |
| October 18, 2024 Filed Jun 12, 2025 16:18 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | Disposition to issuerCommon Stock Purchase Warrant (right to buy) · Derivative | 6,000 | Not disclosed Strike: $25.13 | Not disclosed |
DisclosureSEC source: 0001437749-25-020194 · rdgdoc.xml · derivative · entry 25 Stolarski Anthony Michael · CIK 0001683425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2027-11-14 F3 · shares: On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's outstanding Future Advance Convertible Promissory Note and Common Stock Purchase Warrants were exchanged for an aggregate of 196,413 shares of common stock pursuant to a letter agreement between the reporting person and the Company. F3 · price: On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's outstanding Future Advance Convertible Promissory Note and Common Stock Purchase Warrants were exchanged for an aggregate of 196,413 shares of common stock pursuant to a letter agreement between the reporting person and the Company. Read SEC document |
| October 18, 2024 Filed Jun 12, 2025 16:18 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | Disposition to issuerCommon Stock Purchase Warrant (right to buy) · Derivative | 6,000 | Not disclosed Strike: $15.00 | Not disclosed |
DisclosureSEC source: 0001437749-25-020194 · rdgdoc.xml · derivative · entry 23 Stolarski Anthony Michael · CIK 0001683425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2027-11-14 F3 · shares: On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's outstanding Future Advance Convertible Promissory Note and Common Stock Purchase Warrants were exchanged for an aggregate of 196,413 shares of common stock pursuant to a letter agreement between the reporting person and the Company. F3 · price: On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's outstanding Future Advance Convertible Promissory Note and Common Stock Purchase Warrants were exchanged for an aggregate of 196,413 shares of common stock pursuant to a letter agreement between the reporting person and the Company. Read SEC document |
| October 18, 2024 Filed Jun 12, 2025 16:18 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | Disposition to issuerCommon Stock Purchase Warrant (right to buy) · Derivative | 89,664 | Not disclosed Strike: $25.13 | Not disclosed |
DisclosureSEC source: 0001437749-25-020194 · rdgdoc.xml · derivative · entry 19 Stolarski Anthony Michael · CIK 0001683425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 89,664 shares Expires 2027-08-05 F3 · shares: On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's outstanding Future Advance Convertible Promissory Note and Common Stock Purchase Warrants were exchanged for an aggregate of 196,413 shares of common stock pursuant to a letter agreement between the reporting person and the Company. F3 · price: On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's outstanding Future Advance Convertible Promissory Note and Common Stock Purchase Warrants were exchanged for an aggregate of 196,413 shares of common stock pursuant to a letter agreement between the reporting person and the Company. Read SEC document |
| October 18, 2024 Filed Jun 12, 2025 16:18 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | Disposition to issuerCommon Stock Purchase Warrant (right to buy) · Derivative | 89,664 | Not disclosed Strike: $15.00 | Not disclosed |
DisclosureSEC source: 0001437749-25-020194 · rdgdoc.xml · derivative · entry 17 Stolarski Anthony Michael · CIK 0001683425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 89,664 shares Expires 2027-08-05 F3 · shares: On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's outstanding Future Advance Convertible Promissory Note and Common Stock Purchase Warrants were exchanged for an aggregate of 196,413 shares of common stock pursuant to a letter agreement between the reporting person and the Company. F3 · price: On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's outstanding Future Advance Convertible Promissory Note and Common Stock Purchase Warrants were exchanged for an aggregate of 196,413 shares of common stock pursuant to a letter agreement between the reporting person and the Company. Read SEC document |
| October 18, 2024 Filed Jun 12, 2025 16:18 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | GrantCommon Stock | 8,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-25-020194 · rdgdoc.xml · nonDerivative · entry 9 Stolarski Anthony Michael · CIK 0001683425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 351,786 F3 · shares: On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's outstanding Future Advance Convertible Promissory Note and Common Stock Purchase Warrants were exchanged for an aggregate of 196,413 shares of common stock pursuant to a letter agreement between the reporting person and the Company. F3 · price: On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's outstanding Future Advance Convertible Promissory Note and Common Stock Purchase Warrants were exchanged for an aggregate of 196,413 shares of common stock pursuant to a letter agreement between the reporting person and the Company. Read SEC document |
| October 18, 2024 Filed Jun 12, 2025 16:18 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | GrantCommon Stock | 9,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-25-020194 · rdgdoc.xml · nonDerivative · entry 8 Stolarski Anthony Michael · CIK 0001683425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 343,286 F3 · shares: On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's outstanding Future Advance Convertible Promissory Note and Common Stock Purchase Warrants were exchanged for an aggregate of 196,413 shares of common stock pursuant to a letter agreement between the reporting person and the Company. F3 · price: On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's outstanding Future Advance Convertible Promissory Note and Common Stock Purchase Warrants were exchanged for an aggregate of 196,413 shares of common stock pursuant to a letter agreement between the reporting person and the Company. Read SEC document |
| October 18, 2024 Filed Jun 12, 2025 16:18 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | GrantCommon Stock | 11,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-25-020194 · rdgdoc.xml · nonDerivative · entry 7 Stolarski Anthony Michael · CIK 0001683425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 334,286 F3 · shares: On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's outstanding Future Advance Convertible Promissory Note and Common Stock Purchase Warrants were exchanged for an aggregate of 196,413 shares of common stock pursuant to a letter agreement between the reporting person and the Company. F3 · price: On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's outstanding Future Advance Convertible Promissory Note and Common Stock Purchase Warrants were exchanged for an aggregate of 196,413 shares of common stock pursuant to a letter agreement between the reporting person and the Company. Read SEC document |
| October 18, 2024 Filed Jun 12, 2025 16:18 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | GrantCommon Stock | 5,100 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-25-020194 · rdgdoc.xml · nonDerivative · entry 6 Stolarski Anthony Michael · CIK 0001683425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 322,786 F3 · shares: On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's outstanding Future Advance Convertible Promissory Note and Common Stock Purchase Warrants were exchanged for an aggregate of 196,413 shares of common stock pursuant to a letter agreement between the reporting person and the Company. F3 · price: On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's outstanding Future Advance Convertible Promissory Note and Common Stock Purchase Warrants were exchanged for an aggregate of 196,413 shares of common stock pursuant to a letter agreement between the reporting person and the Company. Read SEC document |
| October 18, 2024 Filed Jun 12, 2025 16:18 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | GrantCommon Stock | 5,400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-25-020194 · rdgdoc.xml · nonDerivative · entry 5 Stolarski Anthony Michael · CIK 0001683425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 317,686 F3 · shares: On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's outstanding Future Advance Convertible Promissory Note and Common Stock Purchase Warrants were exchanged for an aggregate of 196,413 shares of common stock pursuant to a letter agreement between the reporting person and the Company. F3 · price: On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's outstanding Future Advance Convertible Promissory Note and Common Stock Purchase Warrants were exchanged for an aggregate of 196,413 shares of common stock pursuant to a letter agreement between the reporting person and the Company. Read SEC document |
| October 18, 2024 Filed Jun 12, 2025 16:18 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | GrantCommon Stock | 76,215 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-25-020194 · rdgdoc.xml · nonDerivative · entry 4 Stolarski Anthony Michael · CIK 0001683425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 312,286 F3 · shares: On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's outstanding Future Advance Convertible Promissory Note and Common Stock Purchase Warrants were exchanged for an aggregate of 196,413 shares of common stock pursuant to a letter agreement between the reporting person and the Company. F3 · price: On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's outstanding Future Advance Convertible Promissory Note and Common Stock Purchase Warrants were exchanged for an aggregate of 196,413 shares of common stock pursuant to a letter agreement between the reporting person and the Company. Read SEC document |
| October 18, 2024 Filed Jun 12, 2025 16:18 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | GrantCommon Stock | 80,698 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-25-020194 · rdgdoc.xml · nonDerivative · entry 3 Stolarski Anthony Michael · CIK 0001683425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 236,071 F3 · shares: On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's outstanding Future Advance Convertible Promissory Note and Common Stock Purchase Warrants were exchanged for an aggregate of 196,413 shares of common stock pursuant to a letter agreement between the reporting person and the Company. F3 · price: On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's outstanding Future Advance Convertible Promissory Note and Common Stock Purchase Warrants were exchanged for an aggregate of 196,413 shares of common stock pursuant to a letter agreement between the reporting person and the Company. Read SEC document |
| January 21, 2024 Filed Jun 12, 2025 16:18 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | GrantCommon Stock Purchase Warrant (right to buy) · Derivative | 9,999 | Not disclosed Strike: $25.13 | Not disclosed |
DisclosureSEC source: 0001437749-25-020194 · rdgdoc.xml · derivative · entry 32 Stolarski Anthony Michael · CIK 0001683425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,999 Underlying: Common Stock · 9,999 shares Expires 2029-01-21 F8 · price: On July 21, 2023, in exchange for $100,000 in cash, the reporting person acquired from the Company an Asset-Backed Secured Promissory Note with a principal amount of $149,992.50. Pursuant to a letter agreement between the Company and the reporting person, dated as of July 21, 2023, the Company agreed to issue to the reporting person on January 21, 2024 a Future Advance Convertible Promissory Note with a principal amount of $149,992.50 and two Common Stock Purchase Warrants, one with an exercise price of $15.00 per share and one with an exercise price of $25.13 per share, each of which were exercisable for 9,999 shares of common stock. Read SEC document |
| January 21, 2024 Filed Jun 12, 2025 16:18 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | GrantCommon Stock Purchase Warrant (right to buy) · Derivative | 9,999 | Not disclosed Strike: $15.00 | Not disclosed |
DisclosureSEC source: 0001437749-25-020194 · rdgdoc.xml · derivative · entry 30 Stolarski Anthony Michael · CIK 0001683425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,999 Underlying: Common Stock · 9,999 shares Expires 2029-01-21 F8 · price: On July 21, 2023, in exchange for $100,000 in cash, the reporting person acquired from the Company an Asset-Backed Secured Promissory Note with a principal amount of $149,992.50. Pursuant to a letter agreement between the Company and the reporting person, dated as of July 21, 2023, the Company agreed to issue to the reporting person on January 21, 2024 a Future Advance Convertible Promissory Note with a principal amount of $149,992.50 and two Common Stock Purchase Warrants, one with an exercise price of $15.00 per share and one with an exercise price of $25.13 per share, each of which were exercisable for 9,999 shares of common stock. Read SEC document |
| January 21, 2024 Filed Jun 12, 2025 16:18 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | GrantFuture Advance Convertible Promissory Note · Derivative | Not disclosed | $149,992.50 Strike: $15.00 | $149,992.50 |
DisclosureSEC source: 0001437749-25-020194 · rdgdoc.xml · derivative · entry 28 Stolarski Anthony Michael · CIK 0001683425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · 9,999 shares Expires 2025-01-21 F8 · reported_value: On July 21, 2023, in exchange for $100,000 in cash, the reporting person acquired from the Company an Asset-Backed Secured Promissory Note with a principal amount of $149,992.50. Pursuant to a letter agreement between the Company and the reporting person, dated as of July 21, 2023, the Company agreed to issue to the reporting person on January 21, 2024 a Future Advance Convertible Promissory Note with a principal amount of $149,992.50 and two Common Stock Purchase Warrants, one with an exercise price of $15.00 per share and one with an exercise price of $25.13 per share, each of which were exercisable for 9,999 shares of common stock. Read SEC document |
| January 21, 2024 Filed Jun 12, 2025 16:18 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | Disposition to issuerAsset-Backed Secured Promissory Note · Derivative | Not disclosed | $0.00 | $149,992.50 |
DisclosureSEC source: 0001437749-25-020194 · rdgdoc.xml · derivative · entry 27 Stolarski Anthony Michael · CIK 0001683425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · Not disclosed shares Expires 2024-01-21 F8 · derivative.exercise_price: On July 21, 2023, in exchange for $100,000 in cash, the reporting person acquired from the Company an Asset-Backed Secured Promissory Note with a principal amount of $149,992.50. Pursuant to a letter agreement between the Company and the reporting person, dated as of July 21, 2023, the Company agreed to issue to the reporting person on January 21, 2024 a Future Advance Convertible Promissory Note with a principal amount of $149,992.50 and two Common Stock Purchase Warrants, one with an exercise price of $15.00 per share and one with an exercise price of $25.13 per share, each of which were exercisable for 9,999 shares of common stock. F8 · derivative.exercise_date: On July 21, 2023, in exchange for $100,000 in cash, the reporting person acquired from the Company an Asset-Backed Secured Promissory Note with a principal amount of $149,992.50. Pursuant to a letter agreement between the Company and the reporting person, dated as of July 21, 2023, the Company agreed to issue to the reporting person on January 21, 2024 a Future Advance Convertible Promissory Note with a principal amount of $149,992.50 and two Common Stock Purchase Warrants, one with an exercise price of $15.00 per share and one with an exercise price of $25.13 per share, each of which were exercisable for 9,999 shares of common stock. F8 · derivative.underlying: On July 21, 2023, in exchange for $100,000 in cash, the reporting person acquired from the Company an Asset-Backed Secured Promissory Note with a principal amount of $149,992.50. Pursuant to a letter agreement between the Company and the reporting person, dated as of July 21, 2023, the Company agreed to issue to the reporting person on January 21, 2024 a Future Advance Convertible Promissory Note with a principal amount of $149,992.50 and two Common Stock Purchase Warrants, one with an exercise price of $15.00 per share and one with an exercise price of $25.13 per share, each of which were exercisable for 9,999 shares of common stock. Read SEC document |
| November 14, 2023 Filed Jun 12, 2025 16:18 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | ConversionFuture Advance Convertible Promissory Note · Derivative | Not disclosed | $0.00 Strike: $15.00 | $103,500.00 |
DisclosureSEC source: 0001437749-25-020194 · rdgdoc.xml · derivative · entry 21 Stolarski Anthony Michael · CIK 0001683425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,900 shares Expires 2023-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · reported_value: Pursuant to the terms of the Future Advance Convertible Promissory Note issued by the Company on November 14, 2022, all principal and accrued interest due as of the maturity date, November 14, 2023, was automatically converted into shares of common stock at a conversion price of $15.00 per share. Read SEC document |
| November 14, 2023 Filed Jun 12, 2025 16:18 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | ConversionCommon Stock | 6,900 | $15.00 | $103,500.00 |
DisclosureSEC source: 0001437749-25-020194 · rdgdoc.xml · nonDerivative · entry 2 Stolarski Anthony Michael · CIK 0001683425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,373 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Pursuant to the terms of the Future Advance Convertible Promissory Note issued by the Company on November 14, 2022, all principal and accrued interest due as of the maturity date, November 14, 2023, was automatically converted into shares of common stock at a conversion price of $15.00 per share. Read SEC document |
| August 05, 2023 Filed Jun 12, 2025 16:18 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | ConversionFuture Advance Convertible Promissory Note · Derivative | Not disclosed | $0.00 Strike: $15.00 | $1,546,710.00 |
DisclosureSEC source: 0001437749-25-020194 · rdgdoc.xml · derivative · entry 15 Stolarski Anthony Michael · CIK 0001683425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 103,114 shares Expires 2023-08-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · reported_value: Pursuant to the terms of the Future Advance Convertible Promissory Note issued by SANUWAVE Health, Inc. (the "Company") on August 5, 2022, all principal and accrued interest due as of the maturity date, August 5, 2023, was automatically converted into shares of common stock at a conversion price of $15.00 per share. Read SEC document |
| August 05, 2023 Filed Jun 12, 2025 16:18 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | ConversionCommon Stock | 103,114 | $15.00 | $1,546,710.00 |
DisclosureSEC source: 0001437749-25-020194 · rdgdoc.xml · nonDerivative · entry 1 Stolarski Anthony Michael · CIK 0001683425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,473 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Pursuant to the terms of the Future Advance Convertible Promissory Note issued by SANUWAVE Health, Inc. (the "Company") on August 5, 2022, all principal and accrued interest due as of the maturity date, August 5, 2023, was automatically converted into shares of common stock at a conversion price of $15.00 per share. Read SEC document |
| July 21, 2023 Filed Jun 12, 2025 16:18 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | GrantAsset-Backed Secured Promissory Note · Derivative | Not disclosed | $100,000.00 | $149,992.50 |
DisclosureSEC source: 0001437749-25-020194 · rdgdoc.xml · derivative · entry 26 Stolarski Anthony Michael · CIK 0001683425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · Not disclosed shares Expires 2024-01-21 F8 · derivative.exercise_price: On July 21, 2023, in exchange for $100,000 in cash, the reporting person acquired from the Company an Asset-Backed Secured Promissory Note with a principal amount of $149,992.50. Pursuant to a letter agreement between the Company and the reporting person, dated as of July 21, 2023, the Company agreed to issue to the reporting person on January 21, 2024 a Future Advance Convertible Promissory Note with a principal amount of $149,992.50 and two Common Stock Purchase Warrants, one with an exercise price of $15.00 per share and one with an exercise price of $25.13 per share, each of which were exercisable for 9,999 shares of common stock. F8 · derivative.exercise_date: On July 21, 2023, in exchange for $100,000 in cash, the reporting person acquired from the Company an Asset-Backed Secured Promissory Note with a principal amount of $149,992.50. Pursuant to a letter agreement between the Company and the reporting person, dated as of July 21, 2023, the Company agreed to issue to the reporting person on January 21, 2024 a Future Advance Convertible Promissory Note with a principal amount of $149,992.50 and two Common Stock Purchase Warrants, one with an exercise price of $15.00 per share and one with an exercise price of $25.13 per share, each of which were exercisable for 9,999 shares of common stock. F8 · derivative.underlying: On July 21, 2023, in exchange for $100,000 in cash, the reporting person acquired from the Company an Asset-Backed Secured Promissory Note with a principal amount of $149,992.50. Pursuant to a letter agreement between the Company and the reporting person, dated as of July 21, 2023, the Company agreed to issue to the reporting person on January 21, 2024 a Future Advance Convertible Promissory Note with a principal amount of $149,992.50 and two Common Stock Purchase Warrants, one with an exercise price of $15.00 per share and one with an exercise price of $25.13 per share, each of which were exercisable for 9,999 shares of common stock. Read SEC document |
| November 14, 2022 Filed Jun 12, 2025 16:18 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | GrantCommon Stock Purchase Warrant (right to buy) · Derivative | 6,000 | Not disclosed Strike: $25.13 | Not disclosed |
DisclosureSEC source: 0001437749-25-020194 · rdgdoc.xml · derivative · entry 24 Stolarski Anthony Michael · CIK 0001683425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2027-11-14 F7 · price: On November 14, 2022, in exchange for $90,000 in cash, the reporting person acquired from the Company a Future Advance Convertible Promissory Note with a principal amount of $90,000 and a conversion price of $15.00 per share of common stock and two warrants (one exercisable for 6,000 shares of common stock at an exercise price of $15.00 per share and the other exercisable for 6,000 shares of common stock at an exercise price of approximately $25.13 per share). Read SEC document |
| November 14, 2022 Filed Jun 12, 2025 16:18 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | GrantCommon Stock Purchase Warrant (right to buy) · Derivative | 6,000 | Not disclosed Strike: $15.00 | Not disclosed |
DisclosureSEC source: 0001437749-25-020194 · rdgdoc.xml · derivative · entry 22 Stolarski Anthony Michael · CIK 0001683425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2027-11-14 F7 · price: On November 14, 2022, in exchange for $90,000 in cash, the reporting person acquired from the Company a Future Advance Convertible Promissory Note with a principal amount of $90,000 and a conversion price of $15.00 per share of common stock and two warrants (one exercisable for 6,000 shares of common stock at an exercise price of $15.00 per share and the other exercisable for 6,000 shares of common stock at an exercise price of approximately $25.13 per share). Read SEC document |
| November 14, 2022 Filed Jun 12, 2025 16:18 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | GrantFuture Advance Convertible Promissory Note · Derivative | Not disclosed | $90,000.00 Strike: $15.00 | $90,000.00 |
DisclosureSEC source: 0001437749-25-020194 · rdgdoc.xml · derivative · entry 20 Stolarski Anthony Michael · CIK 0001683425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · 6,000 shares Expires 2023-11-14 F7 · reported_value: On November 14, 2022, in exchange for $90,000 in cash, the reporting person acquired from the Company a Future Advance Convertible Promissory Note with a principal amount of $90,000 and a conversion price of $15.00 per share of common stock and two warrants (one exercisable for 6,000 shares of common stock at an exercise price of $15.00 per share and the other exercisable for 6,000 shares of common stock at an exercise price of approximately $25.13 per share). Read SEC document |
| August 05, 2022 Filed Jun 12, 2025 16:18 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | GrantCommon Stock Purchase Warrant (right to buy) · Derivative | 89,664 | Not disclosed Strike: $25.13 | Not disclosed |
DisclosureSEC source: 0001437749-25-020194 · rdgdoc.xml · derivative · entry 18 Stolarski Anthony Michael · CIK 0001683425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,664 Underlying: Common Stock · 89,664 shares Expires 2027-08-05 F6 · price: On August 5, 2022, in exchange for the discharge of $1,344,966 owed by the Company to the reporting person, the reporting person acquired from the Company a Future Advance Convertible Promissory Note with a principal amount of $1,344,966 and a conversion price of $15.00 per share of common stock and two warrants (one exercisable for 89,664 shares of common stock at an exercise price of $15.00 per share and the other exercisable for 89,664 shares of common stock at an exercise price of approximately $25.13 per share). Read SEC document |
| August 05, 2022 Filed Jun 12, 2025 16:18 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | GrantCommon Stock Purchase Warrant (right to buy) · Derivative | 89,664 | Not disclosed Strike: $15.00 | Not disclosed |
DisclosureSEC source: 0001437749-25-020194 · rdgdoc.xml · derivative · entry 16 Stolarski Anthony Michael · CIK 0001683425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,664 Underlying: Common Stock · 89,664 shares Expires 2027-08-05 F6 · price: On August 5, 2022, in exchange for the discharge of $1,344,966 owed by the Company to the reporting person, the reporting person acquired from the Company a Future Advance Convertible Promissory Note with a principal amount of $1,344,966 and a conversion price of $15.00 per share of common stock and two warrants (one exercisable for 89,664 shares of common stock at an exercise price of $15.00 per share and the other exercisable for 89,664 shares of common stock at an exercise price of approximately $25.13 per share). Read SEC document |
| August 05, 2022 Filed Jun 12, 2025 16:18 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | GrantFuture Advance Convertible Promissory Note · Derivative | Not disclosed | $1,344,966.00 Strike: $15.00 | $1,344,966.00 |
DisclosureSEC source: 0001437749-25-020194 · rdgdoc.xml · derivative · entry 14 Stolarski Anthony Michael · CIK 0001683425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · 89,664 shares Expires 2023-08-05 F6 · reported_value: On August 5, 2022, in exchange for the discharge of $1,344,966 owed by the Company to the reporting person, the reporting person acquired from the Company a Future Advance Convertible Promissory Note with a principal amount of $1,344,966 and a conversion price of $15.00 per share of common stock and two warrants (one exercisable for 89,664 shares of common stock at an exercise price of $15.00 per share and the other exercisable for 89,664 shares of common stock at an exercise price of approximately $25.13 per share). Read SEC document |
| August 28, 2019 Filed Aug 28, 2019 14:52 UTC | SANUWAVE Health, Inc. SNWW · Entity 7321 | PurchaseCommon stock | 10,811,864 | $0.11 | $1,189,305.04 |
DisclosureSEC source: 0001654954-19-010090 · section16.xml · nonDerivative · entry 2 Stolarski Anthony Michael · CIK 0001683425 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,011,490 Read SEC document |
| August 26, 2019 Filed Aug 28, 2019 14:52 UTC | SANUWAVE Health, Inc. SNWW · Entity 7321 | GrantStock option · Derivative | 50,000 | $0.00 Strike: $0.15 | $0.00 |
DisclosureSEC source: 0001654954-19-010090 · section16.xml · derivative · entry 3 Stolarski Anthony Michael · CIK 0001683425 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common stock, $0.001 par value · 50,000 shares Expires 2029-08-26 Read SEC document |
| May 31, 2019 Filed Jun 12, 2025 16:18 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | GrantClass O Warrant (right to buy) · Derivative | 533 | $0.00 Strike: $41.25 | $0.00 |
DisclosureSEC source: 0001437749-25-020194 · rdgdoc.xml · derivative · entry 13 Stolarski Anthony Michael · CIK 0001683425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 533 Underlying: Common Stock · 533 shares Expires 2019-09-03 F5 · shares: On May 31, 2019, the Company extended the expiration date of the Class O Warrants to September 3, 2019. Read SEC document |
| May 31, 2019 Filed Jun 12, 2025 16:18 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | Disposition to issuerClass O Warrant (right to buy) · Derivative | 533 | $0.00 Strike: $41.25 | $0.00 |
DisclosureSEC source: 0001437749-25-020194 · rdgdoc.xml · derivative · entry 12 Stolarski Anthony Michael · CIK 0001683425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 533 shares Expires 2019-06-28 F5 · shares: On May 31, 2019, the Company extended the expiration date of the Class O Warrants to September 3, 2019. Read SEC document |
| April 24, 2019 Filed Apr 25, 2019 07:31 UTC | SANUWAVE Health, Inc. SNWW · Entity 7321 | Purchasecommon stock | 2,475,000 | $0.08 | $198,000.00 |
DisclosureSEC source: 0001654954-19-004754 · section16.xml · nonDerivative · entry 1 Stolarski Anthony Michael · CIK 0001683425 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,199,626 Read SEC document |
| April 24, 2019 Filed Aug 28, 2019 14:52 UTC | SANUWAVE Health, Inc. SNWW · Entity 7321 | PurchaseCommon stock | 225,000 | $0.08 | $18,000.00 |
DisclosureSEC source: 0001654954-19-010090 · section16.xml · nonDerivative · entry 1 Stolarski Anthony Michael · CIK 0001683425 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,199,626 Read SEC document |
| March 01, 2019 Filed Jun 12, 2025 16:18 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | GrantClass O Warrant (right to buy) · Derivative | 533 | $0.00 Strike: $41.25 | $0.00 |
DisclosureSEC source: 0001437749-25-020194 · rdgdoc.xml · derivative · entry 11 Stolarski Anthony Michael · CIK 0001683425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 533 Underlying: Common Stock · 533 shares Expires 2019-06-28 F4 · shares: On March 1, 2019, the Company extended the expiration date of the Class O Warrants to June 28, 2019. Read SEC document |
| March 01, 2019 Filed Jun 12, 2025 16:18 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | Disposition to issuerClass O Warrant (right to buy) · Derivative | 533 | $0.00 Strike: $41.25 | $0.00 |
DisclosureSEC source: 0001437749-25-020194 · rdgdoc.xml · derivative · entry 10 Stolarski Anthony Michael · CIK 0001683425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 533 shares Expires 2019-03-17 F4 · shares: On March 1, 2019, the Company extended the expiration date of the Class O Warrants to June 28, 2019. Read SEC document |
| September 20, 2018 Filed Sep 28, 2018 14:13 UTC | SANUWAVE Health, Inc. SNWW · Entity 7321 | GrantStock Option · Derivative | 350,000 | $0.00 Strike: $0.21 | $0.00 |
DisclosureSEC source: 0001654954-18-010626 · section16.xml · derivative · entry 1 Stolarski Anthony Michael · CIK 0001683425 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock, $0.001 par value · 350,000 shares Expires 2028-09-20 F1 · derivative.exercise_date: This warrant is exercisable at date of issuance, September 20, 2018. Read SEC document |
| January 10, 2018 Filed Jan 19, 2018 10:44 UTC | SANUWAVE Health, Inc. SNWW · Entity 7321 | GrantClass N Warrants · Derivative | 1,545,455 | $0.00 Strike: $0.11 | $0.00 |
DisclosureSEC source: 0001654954-18-000555 · section16.xml · derivative · entry 3 Stolarski Anthony Michael · CIK 0001683425 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,545,455 Underlying: Common Stock, $0.001 par value · 1,545,455 shares Expires 2019-03-17 F2 · derivative.exercise_date: These options were issued to Premier Shockwave, Inc. which is wholly owned by Anthony Michael Stolarski. The warrants are exercisable at date of issuance. Read SEC document |
| December 11, 2017 Filed Jan 19, 2018 10:44 UTC | SANUWAVE Health, Inc. SNWW · Entity 7321 | GrantClass O Warrants · Derivative | 200,000 | $0.00 Strike: $0.11 | $0.00 |
DisclosureSEC source: 0001654954-18-000555 · section16.xml · derivative · entry 1 Stolarski Anthony Michael · CIK 0001683425 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock, $0.001 par value · 200,000 shares Expires 2019-03-17 F1 · derivative.exercise_date: This warrant is exercisable at date of issuance, December 11, 2017. Read SEC document |
| November 03, 2017 Filed Jan 19, 2018 10:44 UTC | SANUWAVE Health, Inc. SNWW · Entity 7321 | GrantClass N Warrants · Derivative | 3,000,000 | $0.00 Strike: $0.11 | $0.00 |
DisclosureSEC source: 0001654954-18-000555 · section16.xml · derivative · entry 2 Stolarski Anthony Michael · CIK 0001683425 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000,000 Underlying: Common Stock, $0.001 par value · 3,000,000 shares Expires 2019-03-17 F2 · derivative.exercise_date: These options were issued to Premier Shockwave, Inc. which is wholly owned by Anthony Michael Stolarski. The warrants are exercisable at date of issuance. Read SEC document |
| June 15, 2017 Filed Jun 29, 2017 09:00 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | GrantOptions · Derivative | 300,000 | $0.00 Strike: $0.11 | $0.00 |
DisclosureSEC source: 0001437749-17-011965 · rdgdoc.xml · derivative · entry 1 Stolarski Anthony Michael · CIK 0001683425 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock, $0.001 par value · 300,000 shares Expires 2027-06-15 F1 · derivative.exercise_date: This option for 300,000 shares fully vested on June 15, 2017. Read SEC document |
| November 09, 2016 Filed Dec 16, 2016 16:30 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | GrantOptions · Derivative | 169,800 | $0.00 Strike: $0.18 | $0.00 |
DisclosureSEC source: 0001437749-16-043473 · rdgdoc.xml · derivative · entry 1 Stolarski Anthony Michael · CIK 0001683425 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,800 Underlying: Common Stock, $0.001 par value · 169,800 shares Expires 2026-11-08 F1 · derivative.exercise_date: This option for 169,800 shares fully vested on November 9, 2016. Read SEC document |
| September 28, 2016 Filed Sep 30, 2016 14:00 UTC | SANUWAVE Health, Inc. SNWV · Entity 7321 | PurchaseCommon Stock | 500,000 | $0.06 | $30,000.00 |
DisclosureSEC source: 0001437749-16-039319 · rdgdoc.xml · nonDerivative · entry 1 Stolarski Anthony Michael · CIK 0001683425 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,724,626 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.